Global Cost-Effectiveness of Cardiac Resynchronization Therapy for Heart Failure

A systematic review of 18 studies evaluating the cost-effectiveness of cardiac resynchronization therapy (CRT) for heart failure. The dataset, compiled by Kaltrina Bajraktari and last updated in May 2026, includes economic outcomes like incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs). Costs were standardized to 2024 euros and assessed against country-specific willingness-to-pay thresholds.

Use Cases

• Compare cost-effectiveness ratios (ICERs) for CRT-P versus CRT-D devices based on the reported ranges.
• Analyze the economic impact of CRT across different healthcare settings mentioned in the review.
• Model budget impact for healthcare systems based on the standardized 2024 euro cost data.
• Assess the value of CRT-P as a high-value therapy based on the review's conclusions.

Strengths

• Includes 18 studies meeting defined inclusion criteria for systematic review.
• Cost data is standardized to 2024 euros, enabling cross-study comparison.
• Explicitly reports ICER ranges (e.g., €3,048-€71,447/QALY for CRT+OMT).

Limitations

• Row count and specific column definitions are unknown, limiting suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 53.9 KB file size suggests a limited, summary-level dataset.

Provenance

Source

figshare

Collection Method

Systematic literature review of Web of Science, PubMed, and Scopus from January 2004 to July 2025.

Time Range

Studies published between 2004 and 2025.

Freshness

Last updated 2026-05-21 12:55:04.

Geography

Global evidence from multiple healthcare settings.